Spasticity and the effect of dantrolene sodium.
D000328:Adult; D000843:Ankle Joint; D002561:Cerebrovascular Disorders / Q000150:complications; D002986:Clinical Trials as Topic; D003620:Dantrolene / Q000008:administration & dosage / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004576:Electromyography; D005260:Female; D006801:Humans; D006827:Hydantoins / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D008959:Models, Neurological; D009103:Multiple Sclerosis / Q000150:complications; D009119:Muscle Contraction; D009125:Muscle Relaxants, Central / Q000627:therapeutic use*; D010919:Placebos; D013035:Spasm / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D013118:Spinal Cord Diseases / Q000150:complications; D014159:Transducers; D014732:Vibration
D006827:Hydantoins; D009125:Muscle Relaxants, Central; D010919:Placebos; D003620:Dantrolene